SCHEMBL23778264

SCHEMBL23778264

CCC1CN(C2CCC(C#N)(c3cccs3)CC2)CCCN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.39
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KCNH2 Q12809 2/20 0.37
PRKCB P05771 4/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CCR2 P41597 1/20 0.33
CHRM3 P20309 1/20 0.33
MC4R P32245 2/20 0.33
MC3R P41968 2/20 0.33
MC1R Q01726 2/20 0.33
DPP4 P27487 1/20 0.33
PREP P48147 1/20 0.33
KMT2A Q03164 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23778274 0.86 CYP2D6 (0.52) CYP2D6ALDH1A1PRKCBMC4RMC3R
SCHEMBL23778231 0.84 CYP2D6 (0.44) CYP2D6ALDH1A1PRKCBKDM4ECCR2
SCHEMBL23778369 0.83 CYP2D6 (0.41) CYP2D6KCNH2PRKCBKDM4EMC4R
SCHEMBL23778436 0.82 CYP2D6 (0.41) CYP2D6PRKCBMC4RMC3RMC1R
SCHEMBL23778336 0.82 CYP2D6 (0.57) CYP2D6ALDH1A1PRKCBKDM1A
SCHEMBL23778310 0.82 CYP2D6 (0.46) CYP2D6KCNH2PRKCBCCR2KMT2A
SCHEMBL23778346 0.81 PRKCB (0.43) CYP2D6KCNH2PRKCBCCR2DPP4
SCHEMBL23778233 0.81 CYP2D6 (0.44) CYP2D6ALDH1A1PRKCBCCR2KMT2A
SCHEMBL23778303 0.81 CYP2D6 (0.38) CYP2D6PRKCBMC4RMC3RMC1R
SCHEMBL23778249 0.81 CYP2D6 (0.43) CYP2D6ALDH1A1SMN1; SMN2PRKCBCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 EP claimed